ES2141671B1 - ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT. - Google Patents

ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

Info

Publication number
ES2141671B1
ES2141671B1 ES9702698A ES9702698A ES2141671B1 ES 2141671 B1 ES2141671 B1 ES 2141671B1 ES 9702698 A ES9702698 A ES 9702698A ES 9702698 A ES9702698 A ES 9702698A ES 2141671 B1 ES2141671 B1 ES 2141671B1
Authority
ES
Spain
Prior art keywords
procedure
pharmaceutical compositions
compositions containing
compound
pyrimidinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES9702698A
Other languages
Spanish (es)
Other versions
ES2141671A1 (en
Inventor
Clotet Joan Huguet
Acin Joan Roca
Rovira Anna Bosch
Bonet Merce Canovas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vita Invest SA
Original Assignee
Vita Invest SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vita Invest SA filed Critical Vita Invest SA
Priority to ES9702698A priority Critical patent/ES2141671B1/en
Publication of ES2141671A1 publication Critical patent/ES2141671A1/en
Application granted granted Critical
Publication of ES2141671B1 publication Critical patent/ES2141671B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

Compuesto pirimidínico activo sobre el sistema nervioso central, procedimiento para su preparación y composiciones farmacéuticas que lo contienen. La presente invención se refiere a un compuesto de fórmula general (I), sus formas estereoisoméricas o mezclas de ellas, y sus sales farmacéuticamente aceptables; a un procedimiento para su obtención y a composiciones farmacéuticas que los contengan. Estos compuestos actúan como antagonistas de los receptores D{sub,2 de la dopamina y 5HT{sub,2 de la serotonina y son eficaces en el tratamiento de la esquizofrenia y otras psicosis relacionadas.Pyrimidinic compound active on the central nervous system, procedure for its preparation and pharmaceutical compositions containing it. The present invention relates to a compound of general formula (I), its stereoisomeric forms or mixtures thereof, and its pharmaceutically acceptable salts; to a procedure for obtaining it and to pharmaceutical compositions containing them. These compounds act as antagonists of the D {sub, 2 dopamine and 5HT {sub, 2 serotonin receptors) and are effective in the treatment of schizophrenia and other related psychoses.

ES9702698A 1997-12-26 1997-12-26 ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT. Expired - Lifetime ES2141671B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9702698A ES2141671B1 (en) 1997-12-26 1997-12-26 ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9702698A ES2141671B1 (en) 1997-12-26 1997-12-26 ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

Publications (2)

Publication Number Publication Date
ES2141671A1 ES2141671A1 (en) 2000-03-16
ES2141671B1 true ES2141671B1 (en) 2001-01-01

Family

ID=8301630

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9702698A Expired - Lifetime ES2141671B1 (en) 1997-12-26 1997-12-26 ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

Country Status (1)

Country Link
ES (1) ES2141671B1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
EP0730594B1 (en) * 1993-11-23 1999-09-08 Janssen Pharmaceutica N.V. 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES
ES2085234B1 (en) * 1994-02-24 1997-01-16 Vita Invest Sa ACTIVE AGENT ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.

Also Published As

Publication number Publication date
ES2141671A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
PA8547901A1 (en) 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY
UY28026A1 (en) 4-PIPERAZINILBENCENOSULFONILINDOLES AND USES OF THE SAME.
ECSP055747A (en) CGRP ANTAGONISTS ELECTED, PROCEDURE FOR PREPARATION, AS WELL AS ITS EMPLOYMENT AS MEDICATIONS
UY27259A1 (en) DERIVATIVES OF DIHIDRO-BENZO B 1, 4- DIAZEPIN-2ONA AS ANTAGONISTS I OF MGLUR2
PA8593101A1 (en) COMPOSITIONS FOR THE TREATMENT OF ABNORMAL CELL GROWTH
ECSP045004A (en) INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF DEPENDING ANDROGEN DISEASES
ECSP066391A (en) [1,8] NAFTIRIDIN-2-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA
UY27322A1 (en) NEW INDOL DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEIVER
AR049883A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION, AND THEIR EMPLOYMENT AS MEDICATIONS
AR029216A1 (en) NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE
UY28150A1 (en) THERAPEUTIC AGENTS
CL2004000918A1 (en) COMPOUNDS DERIVED FROM QUINUCLIDINA, ANTAGONISTS OF THE M3 MUSCARINIC RECEIVER; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND TO TREAT AN ANTI-INFLAMMATORY OR ALLERGIC CONDITION, IN PARTICULAR OF THE RESPIRATORY ROADS
GT200000011A (en) USE OF SUBSTITUTED AND DERIVATIVE ISOXAZOLCARBOXILIC ACIDS AND NEW MATERIALS.
AR023574A1 (en) TETRACICLIC AZEPININDOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS TO PREPARE A MEDICINAL PRODUCT, AND INTERMEDIARIES
ECSP034830A (en) SUBSTITUTED DERIVATIVES OF CICLOHEXANO-1,4- DIAMINE
PA8580301A1 (en) NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
AR035153A1 (en) CARBOXAMID DERIVATIVES AND DIHYDROBENZODIOXINE KETONES
UY26729A1 (en) HETEROCYCLIC ALKYLAMINES AS ANTAGONISTS OF MUSCARINIC RECEPTORS
PA8589601A1 (en) INDAZOL DERIVATIVES AS CRF ANTAGONISTS
GT200100181A (en) DERIVATIVES OF QUINAZOLINE AS ALFA-1 ADRENERGIC ANTAGONISTS.
UY27786A1 (en) ISOQUINOLINE DERIVATIVES.
PA8589801A1 (en) AMINOALCOXYINDOLS
AR018162A1 (en) SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION
AR037611A1 (en) COMPOUNDS DERIVED FROM AMINO-TETRALINA, ITS USE, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000316

Kind code of ref document: A1

Effective date: 20000316

FA2A Application withdrawn

Effective date: 20031120